J&J’s Duato to replace departing Gorsky as board chair

The board reshuffling will consolidate Duato’s leadership of J&J as the company absorbs a big medtech acquisition and nears a planned spin out of its consumer health division.

By Delilah Alvarado • Dec. 2, 2022

Large pharmas probe takeover of Horizon Therapeutics

The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.

By Ned Pagliarulo • Updated Nov. 30, 2022

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Roche pulls Tecentriq in bladder cancer, completing sweep of ‘dangling’ accelerated approvals

The pharma will no longer market the immunotherapy in the U.S. for urothelial carcinoma, the indication for which the drug was first approved six years ago.

By Jonathan Gardner • Nov. 29, 2022

Is your gross-to-net strategy ready for uncertainty?

Whether economic times are good, bad or somewhere in between, life science companies benefit from a holistic, centralized approach, including technological, financial, operational and regulatory considerations for GtN management and predictability of GtN rates.

Nov. 28, 2022

Novartis, research group to advance new kind of malaria drug into late-stage test

The Swiss pharma and the Medicines for Malaria Venture plan to start a Phase 3 trial of a non-artemisinin combination treatment next year.

By Delilah Alvarado • Nov. 23, 2022

Merck to buy blood cancer biotech Imago for $1.35B

The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline beyond the top-selling Keytruda.

By Christopher Newman • Nov. 21, 2022

Merck KGaA outlines plan to rev up drug R&D

The German company aims to, on average, launch a new medicine or major treatment indication every 18 months in a bid to boost its pharma business.

By Ned Pagliarulo • Nov. 21, 2022

Teva taps Sandoz veteran to take over CEO post from Schultz

Richard Francis will take over for the retiring Kåre Schultz on Jan. 1. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt.

By Jonathan Gardner • Nov. 21, 2022

Pfizer, BioNTech start study testing next COVID-19 vaccine

The new candidate is meant to provide broader immunity over a longer period of time and is part of the companies’ strategy to stay ahead of a shifting coronavirus threat.

By Delilah Alvarado • Nov. 17, 2022

Regeneron teams up with CytomX to develop dual-targeting cancer drugs

Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than existing treatments.  

By Christopher Newman • Nov. 17, 2022

Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs

Only a small fraction of the companies Lilly evaluates get into its incubator, according to Gilmore. Here’s how the big pharma selects them.

By Gwendolyn Wu • Nov. 15, 2022

Trial failures end latest hope for Roche’s Alzheimer’s drug

Eight years after gantenerumab failed a Phase 3 study, the drug came up short in late-stage testing again, proving unable to meaningfully slow cognitive decline in two closely watched trials. 

By Delilah Alvarado , Ben Fidler • Nov. 14, 2022

Crossing the new real world data landscape

Learn about key factors and trends in RWE and why a data luminary is crucial to your success.

Nov. 14, 2022

Under FDA pressure, GSK limits use of ovarian cancer drug

The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology. 

By Jonathan Gardner • Nov. 11, 2022

EMA backs restrictions on certain immune-regulating drugs

Once the European Commission signs off, use of several so-called JAK inhibitors sold by Eli Lilly, Pfizer and other drugmakers will be limited among smokers and patients who are at high risk of certain health complications. 

By Christopher Newman • Nov. 11, 2022

Pharma earnings outline drug law’s looming impact on sales, development

While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.

By Christopher Newman • Nov. 9, 2022

Ipsen drug shows benefit in pancreatic cancer, lifting shares of ghost company

Adding Onivyde to chemotherapy helped patients live longer, a finding that could result in increased payouts to shareholders in the drug’s developer, Merrimack, which laid off all of its employees in 2019. 

By Jonathan Gardner • Nov. 9, 2022

Early data hint at benefit for Amgen’s obesity drug

Newly released study results suggest treatment could lead to quicker weight loss, on less frequent dosing, than therapies from Eli Lilly and Novo Nordisk.

By Jonathan Gardner • Nov. 8, 2022

Novavax details trial results for omicron-targeting booster shots

A reformulated booster aimed at an earlier omicron subvariant outperformed Novavax’s current vaccine, but a bivalent version did not significantly raise antibody levels.

By Delilah Alvarado • Nov. 8, 2022

Viatris to buy two eye drug developers in deals worth up to $750M

The generics company is acquiring Oyster Point Pharma and the privately held Famy Life Sciences in a move aimed at creating an ophthalmology business.

By Delilah Alvarado • Updated Nov. 7, 2022

GSK myeloma drug comes up short in confirmatory test

The drug, Blenrep, did not outperform a standard treatment in relapsed or refractory multiple myeloma, setting back GSK's plans to confirm the conditional approval it received in 2020.  

By Ned Pagliarulo • Nov. 7, 2022

Amgen’s Lumakras launch slows, shifting attention to other drugs

Sales of the closely watched lung cancer medicine fell short of analysts’ projections, adding to doubts about its market opportunity. 

By Christopher Newman • Nov. 4, 2022

Pfizer, BioNTech data support new Covid booster’s advantage over original vaccine

Follow-up data show the omicron-adapted shot boosted antibodies against the variant in older adults by more than the companies’ original version.

By Delilah Alvarado • Nov. 4, 2022

Moderna cuts sales forecasts for its COVID-19 vaccine

The biotech dialed back its financial projections after reporting lower-than-expected sales for the shot, which currently remains the company’s only marketed product. 

By Delilah Alvarado • Nov. 3, 2022

Novo obesity drug sales lag as manufacturing problems persist

Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.

By Jonathan Gardner • Nov. 2, 2022